AU2019315952A1 - Adjuvant effect of the TLR1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease - Google Patents

Adjuvant effect of the TLR1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease Download PDF

Info

Publication number
AU2019315952A1
AU2019315952A1 AU2019315952A AU2019315952A AU2019315952A1 AU 2019315952 A1 AU2019315952 A1 AU 2019315952A1 AU 2019315952 A AU2019315952 A AU 2019315952A AU 2019315952 A AU2019315952 A AU 2019315952A AU 2019315952 A1 AU2019315952 A1 AU 2019315952A1
Authority
AU
Australia
Prior art keywords
cells
diprovocim
group
mice
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019315952A
Other languages
English (en)
Inventor
Bruce Beutler
Ying Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2019315952A1 publication Critical patent/AU2019315952A1/en
Priority to AU2025204146A priority Critical patent/AU2025204146A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001118—Receptors for colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001121—Receptors for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001124—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001128—CD44 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A61K39/001159—Matrix metalloproteinases [MMP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
AU2019315952A 2018-08-02 2019-07-31 Adjuvant effect of the TLR1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease Abandoned AU2019315952A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204146A AU2025204146A1 (en) 2018-08-02 2025-06-03 Adjuvant effect of the TLR1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862713823P 2018-08-02 2018-08-02
US62/713,823 2018-08-02
PCT/US2019/044421 WO2020028532A1 (en) 2018-08-02 2019-07-31 Adjuvant effect of the tlr1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204146A Division AU2025204146A1 (en) 2018-08-02 2025-06-03 Adjuvant effect of the TLR1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease

Publications (1)

Publication Number Publication Date
AU2019315952A1 true AU2019315952A1 (en) 2021-03-04

Family

ID=69232110

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019315952A Abandoned AU2019315952A1 (en) 2018-08-02 2019-07-31 Adjuvant effect of the TLR1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease
AU2025204146A Pending AU2025204146A1 (en) 2018-08-02 2025-06-03 Adjuvant effect of the TLR1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025204146A Pending AU2025204146A1 (en) 2018-08-02 2025-06-03 Adjuvant effect of the TLR1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease

Country Status (10)

Country Link
US (1) US20210315992A1 (https=)
EP (1) EP3829571B1 (https=)
JP (1) JP2021533134A (https=)
KR (1) KR20210029280A (https=)
CN (1) CN113164445A (https=)
AU (2) AU2019315952A1 (https=)
BR (1) BR112021001992A2 (https=)
CA (1) CA3108515A1 (https=)
IL (1) IL280584B2 (https=)
WO (1) WO2020028532A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
MX2022011765A (es) 2020-03-26 2022-11-09 Provectus Pharmatech Inc Usos novedosos de xantenos halogenados en oncologia y virologia.
JP2023527792A (ja) 2020-05-27 2023-06-30 アキシャル セラピューティクス，インク． Ｔｌｒ２調節剤化合物、医薬組成物、及びそれらの使用
CN115697363A (zh) * 2020-07-14 2023-02-03 Dic株式会社 细胞杀伤性t细胞(ctl)活化用组合物
US20250367166A1 (en) * 2022-04-29 2025-12-04 The Scripps Research Institute Next generation diprovocims that activate the innate and adaptive immune response

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5180806A (en) 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
US6489354B1 (en) 1999-03-02 2002-12-03 Merck & Co., Inc. 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
DK1418905T3 (da) * 2001-08-08 2007-09-10 Pentraxin Therapeutics Ltd Terapeutisk middel til depletering af en uönsket proteinpopulation fra plasma
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
CA2636424A1 (en) * 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
EP2981281B1 (en) * 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9918959B2 (en) * 2014-08-06 2018-03-20 The Board Of Regents Of The University Of Texas System TLR-independent small molecule adjuvants
CA2974956A1 (en) * 2015-01-29 2016-08-04 The Trustees Of The University Of Pennsylvania Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
MX2017012939A (es) * 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
FI3436048T3 (fi) * 2016-03-31 2025-09-15 Biontech Us Inc Neoantigeeneja ja niiden käyttömenetelmiä
KR102522730B1 (ko) 2016-06-29 2023-04-19 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 디프로보심: 새로운 강력한 부류의 tlr 작용제
US20180088749A1 (en) 2016-09-26 2018-03-29 Uber Technologies, Inc. Customized content generation for a user interface for a network service
US20180169224A1 (en) 2016-12-12 2018-06-21 Wisconsin Alumni Research Foundation Tlr agonists for reducing activation-induced pd-1 expression on t cells and methods of use

Also Published As

Publication number Publication date
JP2021533134A (ja) 2021-12-02
WO2020028532A1 (en) 2020-02-06
US20210315992A1 (en) 2021-10-14
IL280584B1 (en) 2025-02-01
AU2025204146A1 (en) 2025-07-17
KR20210029280A (ko) 2021-03-15
AU2025204146A9 (en) 2026-03-19
EP3829571C0 (en) 2025-04-09
BR112021001992A2 (pt) 2021-05-04
EP3829571A1 (en) 2021-06-09
CA3108515A1 (en) 2020-02-06
EP3829571B1 (en) 2025-04-09
IL280584B2 (en) 2025-06-01
CN113164445A (zh) 2021-07-23
IL280584A (en) 2021-03-25
EP3829571A4 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
EP3829571B1 (en) Adjuvant effect of the tlr1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate cancerous or infectious diseases
Gause et al. Immunological principles guiding the rational design of particles for vaccine delivery
KR100717901B1 (ko) 4-1ｂｂ 및/또는 ｃｄ40의 생체내 격발을 통한 항종양ｃｔｌ 면역성 유발
Zhu et al. Lipopeptide epitopes extended by an Nϵ‐palmitoyl‐lysine moiety increase uptake and maturation of dendritic cells through a Toll‐like receptor‐2 pathway and trigger a Th1‐dependent protective immunity
EP1434596B1 (en) Enhancement of immune responses by agonist 4-1bb-antibodies
Szomolanyi-Tsuda et al. T-cell-independent antiviral antibody responses
JP6698541B2 (ja) 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬
CA3049842A1 (en) Construct-peptide compositions and methods of use thereof
JP2015529676A (ja) 作用物質および方法
EP2800762A1 (en) Native and agonist ctl epitopes of the muc1 tumor antigen
CN112088009A (zh) 用于癌症免疫疗法的表达免疫检查点阻断物的溶瘤痘苗病毒
Masuko et al. Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy
CN103458924A (zh) 含有4-1bbl的佐剂组合物
US11479604B2 (en) Immunomodulatory peptides and methods for modulating the immune system in a subject
Szomolanyi‐Tsuda et al. Acquired immunity against virus infections
US20240415828A1 (en) Tlr7 agonist and combinations for cancer treatment
US20050255106A1 (en) Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
KR20160127711A (ko) 유비퀴티닐화 단백질
Sultana Studies on CD40mAb-adjuvanted conjugate vaccines.
AU2022327884A1 (en) Pharmaceutical composition and method for treatment or prevention of cancer
Zeng et al. Soluble Proteins Induce Strong CD8+ T Cell
Solano Supramolecular Peptide Nanofibers for Active Immunotherapy
Mansoor et al. Genetically Modified T Cell Therapy Optimisation of the Chimeric T Cell Receptor for Cancer Therapy
JP2014132030A (ja) 免疫原性組成物およびその使用

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted